Reasons for performing study: Synthetic glucocorticoids are used to treat inflammatory conditions in horses. In other pregnant animals, glucocorticoids are given to stimulate fetal maturation with long-term metabolic consequences for the offspring if given preterm. However, their metabolic effects during equine pregnancy remain unknown. Objective: Thus, this study investigated the metabolic effects of dexamethasone administration on pregnant pony mares and their foals after birth. Study design: Experimental study. Methods: A total of 3 doses of dexamethasone (200 lg/kg bwt i.m.) were given to 6 pony mares at 48 h intervals beginning at %270 days of pregnancy. Control saline injections were given to 5 mares using the same protocol. After fasting overnight, pancreatic b cell responses to exogenous glucose were measured in the mares before, during and after treatment. After birth, pancreatic b cell responses to exogenous glucose and arginine were measured in the foals at 2 and 12 weeks. Results: In mares during treatment, dexamethasone but not saline increased basal insulin concentrations and prolonged the insulin response to exogenous glucose. Basal insulin and glucose concentrations still differed significantly between the 2 groups 72 h post treatment. Dexamethasone treatment significantly reduced placental area but had little effect on foal biometry at birth or subsequently. Foal b cell function at 2 weeks was unaffected by maternal treatment. However, by 12 weeks, pancreatic b cell sensitivity to arginine, but not glucose, was less in foals delivered by dexamethasone-than saline-treated mares. Conclusions: Dexamethasone administration induced changes in maternal insulin-glucose dynamics, indicative of insulin resistance and had subtle longer term effects on post natal b cell function of the foals. The programming effects of dexamethasone in horses may be mediated partially by altered maternal metabolism and placental growth.
Introduction
In man, synthetic glucocorticoids are used given routinely to healthy pregnant women threatened with preterm delivery to improve neonatal viability of their infants [1] . During pregnancy, these drugs mimic the normal rise in endogenous glucocorticoids seen in fetuses near term, which promotes maturation of fetal tissues and, in some species, also triggers labour [2, 3] . In mares, synthetic glucocorticoids appear to be less effective at inducing delivery in late gestation and can be detrimental to pregnancy outcome if given too close to full term [4, 5] . However, early delivery of viable foals has been observed in response to maternal dexamethasone administration between 315 and 322 days of gestation [6] [7] [8] .
Relatively little is known about the maternal metabolic outcomes of dexamethasone treatment in pregnant animals, although pregnancy is associated with a natural state of insulin resistance in many species including the horse [9] [10] [11] . Indeed, there are many more studies of the metabolic consequences of this treatment for the post natal offspring than for the pregnant mother per se [12] [13] [14] . Studies in pregnant rats, guinea pigs, sheep and nonhuman primates have shown that maternal administration of synthetic glucocorticoids during late pregnancy alters fetal development and induces post natal abnormalities in cardiovascular, metabolic and endocrine function in the offspring [2, [11] [12] [13] . In particular, there are changes in glucose metabolism in the adult offspring, which are due, in part, to altered secretion and action of insulin [12] [13] [14] . However, nothing is known about the metabolic consequences of dexamethasone treatment of pregnant horses either for the mare or her foal after birth, although there are changes in maternal progestagen concentrations and adrenocortical function of the newborn foal after dexamethasone administration to pregnant mares near term [8] . This study, therefore, examined pancreatic b cell function in pregnant mares and their foals after birth following dexamethasone administration in late gestation. Post natally, pancreatic b cell function was tested using both glucose and arginine, as they act through different mechanisms to secret insulin and are known to be effective in both fetal and newborn foals [15] [16] [17] .
Materials and methods

Animals
A total of 11 pregnant pony mares of known gestational age were used. They were housed in individual stables and fed hay ad libitum and concentrates twice a day (mare and young stock mix a , 1 kg/100 kg 12.5 MJ/kg, 14% crude protein, 4.5% oils, 8% crude fibre). On the day of birth the foals were treated with equine tetanus antitoxin (1000 iu) b and remained with their mothers throughout the experimental period. One foal from a control mare had limb deformities and was subjected to euthanasia at 48 h on veterinary advice. At the end of the entire study, the animals were either rehomed (n = 9 mares, n = 5 foals) or euthanised (n = 2 mares, n = 5 foals; 200 mg/kg bodyweight [bwt] sodium pentobarbitone [Pentoject]) c to provide tissue for other research studies.
Experimental procedures
Mares: The mares were assigned randomly to be treated intramuscularly (i.m.) with either dexamethasone (200 lg/kg bwt i.m, Dexamethasone 21-phosphate d in 0.9% w/v saline, n = 6) or the equivalent volume of saline as a control (0.9% w/v, n = 5) on 3 occasions at 48 h intervals beginning at a mean gestational age of 267.0 AE 12.0 days that was similar in the 2 treatment groups (Saline, 271.0 AE 19.0 days; n = 5: Dexamethasone, 263.0 AE 16.0 days; n = 6; P>0.05, term~335 days). The 2 groups were of similar bodyweight at the onset of treatment (Saline, 273.0 AE 19.0 kg; n = 5: Dexamethasone, 251.0 AE 6.5 kg; n = 6; P>0.05). A total of 4 days before injections began, a long stay catheter (16 gauge) e with an extension tube was inserted into a jugular vein under local anaesthesia (IntraEpicaine) f . Between 08.00-08.30 h daily, the jugular catheter was flushed with heparinised saline to maintain patency. An intravenous (i.v.) glucose tolerance test was carried out 48 h before treatment began (pretreatment), then again 24 h after the second injection (during treatment) and finally 72 h after the third injection of saline or dexamethasone (post treatment). In each test, blood samples (10 ml) were taken at 30, 15 and 0 min before and at 5, 15, 30, 45, 60, 90 and 120 min after i.v. administration of glucose (0.5 g/kg bwt, Dextrose, 40% w/v) f for the measurement of plasma glucose and insulin at all times and plasma L-lactate at 0 min. After glucose administration, the catheter was flushed with 20 ml of saline (0.9% w/v). Mares were without food overnight before the glucose tolerance test and did not receive their morning ration of concentrates until after the glucose tolerance test was complete. Water was freely available at all times. At the end of the experimental period, the catheter was removed and the mares monitored twice daily for signs of impending delivery.
Foals: At birth, the foal and placenta were weighed and measured. Placental area was measured by laying the placenta on a plastic sheet, cutting around the area and weighing the resulting template. Using the weight of a known area of the plastic sheeting, the total placental area was calculated. After birth, the foals were weighed and measured weekly until 12 weeks. Blood samples (5 ml) were taken by venipuncture from the jugular vein of all foals on the day of birth (Day 1) for measurement of plasma cortisol concentrations. At 10-12 days of post natal age, the jugular vein was catheterised as described for the mares. Beginning at 2 weeks, glucose (0.5 g/kg bwt, Dextrose, 40% w/v) f followed by arginine (100 mg/kg bwt) g were given i.v. over 5 min at a 48-72 h interval at doses known to be effective at stimulating insulin secretion in newborn foals [16] . On each occasion, the catheter was flushed with saline (10 ml, 0.9% w/v). Blood samples (5 ml) were taken from the jugular catheter at 30, 15 and 0 min before and at 5, 15, 30, 45, 60, 90 and 120 min after substance administration. At 2 weeks, foals remained with their mothers throughout the experiments but were muzzled to prevent suckling from 1 h before sampling began until the end of the sampling period. At the end of this series of experiments, the jugular catheter was removed and the foal was recatheterised at %12 weeks. The pancreatic b cell challenges were then repeated in the same order using the same protocol as at 2 weeks. To minimise stress, the older foals were not muzzled but were separated from their mothers by a barrier which allowed sight and interaction but no suckling for 3 h before sampling began until the end of the sampling period.
Biochemical analyses
Blood samples were added to tubes containing either heparin or EDTA and centrifuged immediately. The plasma was stored at -20°C until analysis of plasma metabolite and hormone concentrations. Plasma glucose and lactate concentrations were measured using a glucose-lactate analyser.
h Plasma a-amino nitrogen concentrations were determined on deproteinised plasma by the colourimetric method of Evans et al. [18] using glycine as a standard as an index of the arginine concentrations. Plasma insulin concentration was measured by an ELISA assay i validated for use with equine plasma [19] . The intra-and interassay coefficients of variation for the insulin assay were 3.4 and 13%, respectively. Plasma cortisol was assessed using an ELISA j validated for equine plasma as described previously [20] . The intra-and interassay coefficients of variation for this assay were 4.3 and 8.9%, respectively.
Data analyses
All values are expressed as mean AE s.e. Statistical comparisons between groups were made using Student's t test, or one or 2-way ANOVA with repeated measures (time) followed by Turkey post hoc test, as appropriate. When time or treatment was identified as significant factors by 2-way ANOVA, the 2 treatment groups were analysed separately by one way ANOVA. The responses to glucose and arginine administration were measured as delta concentrations from baseline values at 0 min. Insulin data was normalised by log transformation, where required. For each challenge, the area under the curve (AUC) for the glucose (AUCG), a-amino nitrogen (AUCAN) and insulin (AUCI) responses was calculated as the integrated plasma concentration after administration of glucose or arginine from 0-120 min above the baseline concentration at 0 min for all positive values. All statistical analyses were performed using Sigma-Stat K and considered significant when P<0.05.
Results
Effects of dexamethasone treatment on pregnant mares
Basal insulin and metabolite concentrations: Plasma concentrations of glucose, lactate and insulin after an overnight fast did not differ between the 2 groups of mares before treatment commenced (Table 1 ). However, 3 days after beginning treatment, fasted concentrations of plasma glucose, lactate and insulin were significantly higher in dexamethasone-than salinetreated animals ( Table 1 ). Three days after finishing dexamethasone treatment, fasting concentrations of lactate and insulin were not significantly different from the pretreatment values (Table 1) . Post treatment fasting levels of insulin were higher in dexamethasone-than saline-treated mares (Table 1 ). In contrast, fasting concentrations of plasma glucose in dexamethasone-treated mares post treatment were lower than both their own pretreatment values and the post treatment concentrations in saline-treated mares (Table 1 ). There were no changes in the fasting concentrations of glucose, lactate or insulin in mares receiving saline with time over the treatment period (Table 1) .
Pancreatic b response to glucose: The increment and maximal concentration of plasma glucose after glucose administration did not differ significantly with time over the treatment period in either group of mares or between the 2 groups of mares at any time over the treatment period (Fig 1a, Table 1 ). The AUCG were also unaffected by treatment (Fig 2a) . In common with previous findings [10] , the insulin response to glucose administration varied widely between pregnant mares, even pretreatment (Fig 2b) . Pretreatment, there were no significant differences in the insulin increment, maximal insulin concentration or time course of the insulin response to glucose between saline-and dexamethasone-treated mares (Table 1 , Fig 1b) . During dexamethasone treatment, the insulin response to glucose was more prolonged than seen in mares receiving saline (Fig 1b) .
The maximum increment and the maximal concentrations of plasma insulin were also greater in the dexamethasone than saline group of mares during treatment (Table 1 ). In the dexamethasone but not the saline-treated mares, the area under the insulin curve (AUCI) during treatment was greater than their respective pretreatment values (Fig 2b) . Relative insulin secretion, measured as the ratio of the AUCI to AUCG, showed the same profile with treatment as the AUCI (Fig 2c) .
Delivery: Mares delivered uneventfully at a mean gestational age of 335.0 AE 2.9 days (Saline, 338.0 AE 0.9 days; n = 5, 2 male and 3 female foals: Dexamethasone, 333.0 AE 5.3 days; n = 6, 3 males 3 females, P>0.05). At delivery, placental weight was similar while placental area was significantly less in dexamethasone than saline-treated mares ( Table 2) .
Effects of dexamethasone treatment on the foals
Biometry: All foals stood and suckled within 1 h of delivery and were classified as mature by clinical criteria [21] . On the day of delivery, plasma cortisol concentrations were similar in foals delivered by dexamethasone (22.3 AE 2.7 ng/ml, n = 6) and saline-treated mares (21.8 AE 4.0 ng/ml, n = 5, P>0.05). At birth, foals of dexamethasone-treated mares tended to be smaller than those of saline-treated mares but there were no statistically significant differences in bodyweight, crown rump length or height at the withers between the 2 groups of newborn foals (P = 0.07, all cases, Table 2 ). Only femur length of the newborn foals was significantly shorter after maternal dexamethasone treatment (Table 2) . Birthweight per cm 2 of placenta was unaffected by maternal treatment (Saline, 3.26 AE 0.18 g/cm 2 , n = 5; Dexamethasone, 3.13 AE 0.20 g/cm 2 , n = 6, P>0.05). None of the morphometric measurements of the foals differed significantly between the 2 treatment groups at either 2 or 12 weeks (Table 2 ). There were also no differences in the growth rate or fractional growth rate of any of the body measurements of the foals between the 2 treatment groups over the first 12 weeks after birth (P>0.05, data not shown). In addition, there were no differences in the plasma cortisol concentrations between the 2 treatment groups at 2 or 12 weeks (2 weeks; Saline, 40.5 AE 4.8 ng/ml, n = 4; Dexamethasone, 40.3 AE 6.2 ng/ml, n = 6: 12 weeks; Saline 27.5 AE 2.6 ng/ ml, n = 4; Dexamethasone, 35.0 AE 3.4 ng/ml, n = 6, P>0.05 both ages) Pancreatic b cell responses: Glucose: At 2 and 12 weeks, there were no significant differences in the basal concentrations of plasma glucose, a-amino nitrogen or insulin before administration of glucose or arginine between the 2 treatment groups (Table 3) . At both ages, there were also no significant differences in the incremental or maximal concentrations of glucose or insulin in response to glucose administration between the 2 treatment groups (Figs 3a and b, Table 3 ). However, the maximal increment and the maximum concentration of plasma glucose and the AUCG were greater at 12 weeks than 2 weeks, irrespective of maternal treatment (Fig 3a, Table 3 ). The insulin response to glucose administration was also more prolonged at 12 than 2 weeks in both treatment groups (Fig 3b) . However, there were no significant differences in AUCI or relative insulin secretion in the foals with either maternal treatment or increasing age (Table 3) . Arginine: The incremental and maximal concentration of plasma a-amino nitrogen in response to arginine administration in the foals was unaffected by maternal treatment at 2 weeks (Fig 3c, Table 3 ). The incremental and maximal concentrations of insulin and the AUCI in response to arginine were unaffected by maternal treatment at this age (Fig 3d, Table 3 ). However, at 12 weeks, the increment in plasma a-amino nitrogen concentration was more prolonged and significantly greater in foals of dexamethasone-treated mares (Fig 3c) . Consequently, relative to controls receiving saline, the AUCAN was significantly greater in 12-week-old foals of dexamethasone-than saline-treated mares (Fig 3d, Table 3 ). The increment in insulin concentration was less in the dexamethasone than saline group of 12-week-old foals at 5 min after arginine administration although not at the later sampling times (Fig 3d) . As a result, relative insulin secretion, the ratio of AUCI to AUCAN, was significantly less in the dexamethasone than saline group of foals at 12 weeks but not at 2 weeks of post natal age (Table 3) . At 12 weeks, the insulin response to arginine administration was more prolonged than in the younger foals, irrespective of maternal treatment (Fig 3d) .
Discussion
The study shows for the first time that treatment of pregnant pony mares at %270 days of gestation with the synthetic glucocorticoid, dexamethasone, induces transient maternal hyperinsulinaemia, indicative of increased insulin resistance. During treatment, basal fasting concentrations of plasma insulin and the increment in plasma insulin in response to exogenous glucose were significantly greater in dexamethasone-treated mares than in control mares receiving saline. The maternal AUCI was also significantly greater during treatment with dexamethasone but not saline. Maternal dexamethasone treatment had no effect on the length of gestation but reduced gross placental area at delivery. Despite these changes, dexamethasone treatment of pregnant mares had relatively little effect on their offspring with only subtle changes in pancreatic b cell function in their 12-week-old foals.
Maternal effects
Several previous studies have shown that dexamethasone at doses similar to those used here induces hyperglycaemia, hyperinsulinaemia and insulin resistance in nonpregnant horses [22] [23] [24] [25] [26] . These changes are seen in response to single and multiple doses of dexamethasone and begin within 2 h of administration with recovery taking up to 2 weeks after multiple dosing [22, 24, 25, 27] . Similar increases in peripheral insulin resistance are seen in nonpregnant horses with hyperadrenocorticism induced by pars intermedia dysfunction [28] . In the current study, dexamethasone treatment of pregnant mares caused fasting hyperinsulinaemia, Values are mean AE s.e. Mares were treated with 3 doses of dexamethasone (i.m. 200 l/kg bwt, n = 6) or saline (i.m. 0.9% w/v, n = 4 -5) at 48 h intervals during late gestation. *Significantly less than value in the saline treated group (P<0.02, t test).
lactacidaemia and an enhanced pancreatic b cell response to exogenous glucose without any changes in glucose dynamics or fasting hyperglycaemia. At this stage of pregnancy, mares are already insulin resistant and have a significant fetoplacental glucose requirement [9, 11, 29] .
Dexamethasone treatment, therefore, appears to further increase maternal insulin resistance without the concomitant changes in glycaemia observed in nonpregnant horses. This suggests that during dexamethasone treatment, any reduction in glucose uptake by insulin resistant maternal tissues is balanced by an increase in glucose transfer to the rapidly growing fetus that is insulin independent [29] . Maternal hyperinsulinaemia and insulin resistance together with elevated whole body glucose disposal have been seen in pregnant rats treated with dexamethasone in late gestation when glucose demands of the gravid uterus are high [30] . Increased lactate production has also been previously observed in response dexamethasone treatment in man and other species [31, 32] . In the current study, the insulin-glucose dynamics of the dexamethasonetreated mares were still abnormal 72 h after ceasing treatment with significant differences in basal fasting concentrations of both insulin and glucose between the 2 treatment groups at this time. Indeed, in dexamethasone-treated mares, fasting glucose concentrations were lower post than pretreatment, although post treatment insulin concentrations were not significantly different from the pretreatment values. Since dexamethasone would have cleared from the maternal circulation by 72 h post treatment [24] , these findings indicate that insulin sensitivity of the dexamethasone-treated mares may have been greater post than pretreatment, consistent with previous findings in nonpregnant horses receiving dexamethasone [23, 26] .
Foal effects
In the current study, dexamethasone treatment had little apparent effect on gestational length or prepartum maturation as all foals were mature at birth and stood and sucked within the normal time, irrespective of maternal treatment [21] . At delivery, placental area was smaller after maternal dexamethasone treatment, consistent with the known growth inhibitory effects of synthetic glucocorticoids on the placenta in other species [13, 33] . This led to a tendency for smaller foals after maternal dexamethasone treatment but only femur length was reduced significantly at birth. In previous studies of dexamethasone administration, foal birthweight was also unaffected, although crown rump length was reduced at dexamethasone doses similar to those used here [6] [7] [8] . In other species, maternal administration of synthetic glucocorticoids at a similar dose and stage of gestation reduces fetal weight and results in lower birthweight [2, [12] [13] [14] . Collectively, these observations suggest that dexamethasone can restrict fetal bone growth but may be less effective at inhibiting growth of fetal somatic tissues in horses than other species. Maternal dexamethasone treatment had little effect on pancreatic b cell sensitivity to glucose of the foals 2 and 12 weeks after birth. The insulin responses of the foals to glucose were similar in the 2 treatment groups at both ages and resembled those published previously for age-matched foals of mares receiving no treatment [34] . In other species, maternal dexamethasone treatment during late pregnancy alters glucose-stimulated insulin secretion in the offspring, although at older post natal ages than studied here [12] [13] [14] . However, there were developmental changes in equine b cell responses to glucose over the first 12 weeks of post natal life, irrespective of maternal treatment. Insulin secretion in response to exogenous glucose switched from a monophasic response at 2 weeks to a more biphasic pattern of response at 12 weeks, without any significant age-related change in AUCI. This resembled the developmental profile of glucose-stimulated insulin secretion seen previously in foals of untreated mares [34] . Since the AUCG was significantly greater at 12 weeks than 2 weeks of age, the current findings suggest that insulin sensitivity decreases with age over the first 12 weeks of post natal life, irrespective of maternal treatment, in keeping with previous findings in older untreated foals [35] .
In contrast to b cell glucose sensitivity, the insulin response to arginine was affected by maternal dexamethasone treatment by the time the foals were 12-weeks-old. The increments in a-amino-nitrogen and AUCAN were greater and the initial insulin increment and relative insulin secretion were less in the dexamethasone-than saline-treated group of 12-week-old foals. Collectively, these findings suggests that arginine may be less effective at stimulating insulin release and that insulin may be less effective at stimulating tissue amino acid uptake in 12-week-old foals after maternal dexamethasone treatment. Arginine depolarises b cells directly through Significantly different from value in the saline treated group at the same age (P<0.05, t test).
ATP-dependent K + channels, whereas glucose acts indirectly on these channels via generation of ATP [15] . In fetal horses, the pancreatic b cell response to glucose but not arginine increases near term indicating that there is prepartum maturation of the insulin secretory pathways upstream of b cell depolarisation [17] . The current findings suggests that maturation of the insulin secretory pathway continues after birth and is influenced by maternal dexamethasone treatment, particularly at and/or downstream of the depolarising K + channels. However, further studies are required to establish the extent to which these changes in b cell sensitivity to arginine are due directly to dexamethasone exposure in utero or indirectly to the maternal metabolic and other physiological alterations that affect perinatal development of the foal. Certainly, maternal glucocorticoid overexposure in late pregnancy is known to influence mammary development and milk quality in the mare [8] .
Conclusions
Maternal dexamethasone treatment has metabolic actions in the mare during late pregnancy but relatively little effect on the growth or pancreatic endocrine function her foal after birth. However, there were treatment differences in placental area and femur length of the foal at birth. There are also differences in the pancreatic b cell response of the foals to arginine after maternal dexamethasone treatment, which became evident between 2 and 12 weeks. This indicates that dexamethasone treatment during pregnancy can have longer term metabolic consequences for the offspring in horses as occurs in other species [12] [13] [14] . Certainly, glucocorticoid overexposure of foals immediately after birth is known to have metabolic and endocrine effects long after weaning [34, 36] . Taken together, the current findings suggest that dexamethasone may have programming Mean AE s.e. increments from basal 0 min values in the plasma concentrations of a) glucose and b) insulin in response to glucose administration at 0 min and c) a-amino nitrogen and d) insulin in response to arginine administration at 0 min in foals at 2 and 12 weeks delivered by mares treated with dexamethasone (filled symbols, n = 6) or saline (open symbols, n = 4). *Significant increment from basal value either for a specific sampling time and treatment group when given singly or for both groups when spanning a range of sampling times (t test, P<0.05). †significantly different from value in the saline treatment group (2-way ANOVA, P<0.05). #significantly different from values at 2 weeks in both treatment groups (2-way ANOVA, P<0.05).
effects during equine pregnancy, possibly due to maternal metabolic changes and placental growth restriction.
